Lixte Biotechnology Holdings, Inc.
LIXT · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.14 | 0.05 | 0.48 |
| FCF Yield | -19.80% | -19.01% | -13.11% | -22.77% |
| EV / EBITDA | -2.03 | -2.27 | -2.24 | -2.61 |
| Quality | ||||
| ROIC | -118.93% | -60.99% | -74.10% | -71.93% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.47 | 0.63 | 0.80 | 0.97 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 14.25% | 5.04% | 37.48% | -16.92% |
| Safety | ||||
| Net Debt / EBITDA | 1.15 | 1.96 | 0.66 | 1.66 |
| Interest Coverage | -428.07 | -225.50 | -138.31 | -937.33 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |